Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Therapeutic Drug Carrier Systems
Fator do impacto: 2.9 FI de cinco anos: 3.72 SJR: 0.573 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimir: 0743-4863
ISSN On-line: 2162-660X

Volumes:
Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v28.i4.20
pages 357-393

Lipid Nanocarriers: Influence of Lipids on Product Development and Pharmacokinetics

Kamla Pathak
Department of Pharmaceutics, Rajiv Academy for Pharmacy, P.O.Chhattikara, Mathura, INDIA
Lav Keshri
Department of Pharmaceutics, Rajiv Academy for Pharmacy, P.O. Chhatikara, Mathura, India
Mayank Shah
Department of Pharmaceutics, Rajiv Academy for Pharmacy, P.O. Chhatikara, Mathura, India

RESUMO

Lipid nanocarriers are on the forefront of the rapidly developing field of nanotechnology with several potential applications in drug delivery. Owing to their size-dependent properties, lipid nanoparticles offer the possibility for development of new therapeutics and an alternative system to other colloidal counterparts for drug administration. An important point to be considered in the selection of a lipid for the carrier system is its effect on the properties of the nanocarrier and also its intended use, as different types of lipids differ in their nature. Researchers around the globe have tapped the potential of solid lipid nanoparticles (SLNs) in developing formulation(s) that can be administered by various routes such as oral, ocular, parenteral, topical, and pulmonary. Since the start of this millennium, a new generation of lipid nanoparticles, namely nanostructured lipid carriers (NLCs), lipid drug conjugates (LDCs), and pharmacosomes, has evolved that have the potential to overcome the limitations of SLNs. The current review article presents broad considerations on the influence of various types of lipids on the diverse characteristics of nanocarriers, encompassing their physicochemical, formulation, pharmacokinetic, and cytotoxic aspects.


Articles with similar content:

Peptide and Protein Delivery Using New Drug Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 4
Ashish Jain, Satish Shilpi, Pooja Hurkat, Aviral Jain, Arvind Gulbake, Sanjay Kumar Jain
Nanoformulations for Delivery of Biomolecules: Focus on Liposomal Variants for siRNA Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 6
Tapan K. Dash , V. Badireenath Konkimalla
Quantum Dots and their Potential Role in Cancer Theranostics
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 6
S. K. Tripathi, Gurvir Kaur, Bhupinder Singh, Rajneet Kaur Khurana, Sonia Kapoor
Exploiting the Tumor Phenotype Using Biodegradable Submicron Carriers of Chemotherapeutic Drugs
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 3-4
Aliasger K. Salem, Sean M. Geary
Engineered PLGA Nanoparticles: An Emerging Delivery Tool in Cancer Therapeutics
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 1
Amit K. Jain, Manasmita Das, Nitin K. Swarnakar, Sanyog Jain